檢索結果 - Vincent A. Miller

Refine Results
  1. 1
    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer 由 Jennifer Clarke, William Pao, Nian Wu, Vincent A. Miller, Andrew B. Lassman

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer 由 Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William Pao

    出版 2011
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Cl... 由 Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, Gregory J. Riely

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma 由 James Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William Pao

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling 由 Angel Qin, Adrienne Johnson, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, Shirish M. Gadgeel

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping 由 Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden 由 Victoria E. Wang, Anatoly Urisman, Lee A. Albacker, Siraj M. Ali, Vincent A. Miller, Rahul Aggarwal, David M. Jablons

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities 由 Sherri Z. Millis, Denis L. Jardim, Lee A. Albacker, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Razelle Kurzrock

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain 由 William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations

    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations 由 Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study

    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study 由 Vineeta Agarwala, Sean Khozin, Gaurav Singal, Claire O’Connell, Deborah Kuk, Gerald Li, Anala Gossai, Vincent A. Miller, Amy P. Abernethy

    出版 2018
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  12. 12
    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors 由 Darren Sigal, Munveer S. Bhangoo, Jonathan A. Hermel, Dean C. Pavlick, Garrett M. Frampton, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation 由 Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    EGFR Mutations in Lung Adenocarcinomas

    EGFR Mutations in Lung Adenocarcinomas 由 Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie W. Rusch, Mark G. Kris, Marc Ladanyi

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib 由 Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, Vincent A. Miller

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers 由 Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies 由 Aaron M. Goodman, Shumei Kato, Philip R. Cohen, Amélie Boichard, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer 由 Vincent A. Miller, James R. Rigas, Prudence A. Francis, Stefan C. Grant, Katherine M.W. Pisters, Mark G. Kris, Karen Woolley, Ennapadam Venkatraman, Robert T. Heelan

    出版 1995
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib 由 William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold Varmus

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors 由 Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: